Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Researchers are doing this study to find out if the combination of the drugs axitinib and
talazoparib is a safe and effective treatment for people with your previously treated
advanced kidney cancer. Researchers will look for the highest dose of talazoparib that causes
few or mild side effects when given in combination with a standard dose of axitinib.